AirMid Critical Care Products, Inc.

AirMid has invented a device that aims to replace the ubiquitous resuscitation-bag, which has not substantively changed since its introduction in the 1950’s. The predicate device can’t be calibrated to deliver controlled breath volume to patients, and it is a root cause of inadvertent over-inflation of the lungs, which tears the alveolar lung tissue. This causes acute lung injury (ALI) in approximately 190,000 patients, leading to more than 74,000 deaths a year.

AirMid's volume controlled manual ventilators aim to replace an FDA "grandfathered" and unimproved 1950’s technology resuscitation-bag, which contributes to causing acute lung injury (ACI) in 190,000 patients each year. Inadvertent overinflation of the lungs results in more than 72,000 deaths a year, and creates $20B in downstream cost of care. The predicate device's U.S. market is <$1.5B.

Basics

  • Number of Employees
    2-10 employees
  • Stage
    Product In Development
  • Founded
    2014
  • Primary Industry

Description

AirMid’s volume controlled manual ventilators aim to replace an FDA “grandfathered” and unimproved 1950’s technology resuscitation-bag, which contributes to causing acute lung injury (ACI) in 190,000 patients each year. Inadvertent overinflation of the lungs results in more than 72,000 deaths a year, and creates $20B in downstream cost of care. The predicate device’s U.S. market is <$1.5B.